Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prosed is a multi-ingredient oral medication used to alleviate symptoms of lower urinary tract infections and inflammation, such as pain, burning, and frequency. It combines several therapeutic classes: methenamine and benzoic acid act as urinary anti-infectives (methenamine converts to formaldehyde in acidic urine); phenyl salicylate provides analgesic and anti-inflammatory effects; hyoscyamine sulfate is an anticholinergic that reduces bladder spasms (hypermotility); and methylene blue serves as a mild antiseptic. It is primarily indicated for cystitis, urethritis, and trigonitis. While the brand name Prosed/DS has been discontinued in the United States, similar multi-ingredient formulations remain available for symptomatic relief of urinary tract conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prosed.